Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

被引：0
|
作者：
Roland Heinig
Marc Lambelet
Johannes Nagelschmitz
Abir Alatrach
Atef Halabi
机构：
[1] Bayer AG,
[2] Research & Development,undefined
[3] Pharmaceuticals,undefined
[4] Clinical Sciences,undefined
[5] CHRESTOS Concept GmbH & Co. KG,undefined
[6] CRS Clinical Research Services Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 628
页数：9
相关论文
共 36 条
  • [1] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment
    Heinig, Roland
    Lambelet, Marc
    Nagelschmitz, Johannes
    Alatrach, Abir
    Halabi, Atef
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (05) : 619 - 628
  • [2] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment
    Heinig, Roland
    Kimmeskamp-Kirschbaum, Nina
    Halabi, Atef
    Lentini, Silvia
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (06): : 488 - 501
  • [3] Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
    Baerfacker, Lars
    Kuhl, Alexander
    Hillisch, Alexander
    Grosser, Rolf
    Figueroa-Perez, Santiago
    Heckroth, Heike
    Nitsche, Adam
    Ergueden, Jens-Kerim
    Gielen-Haertwig, Heike
    Schlemmer, Karl-Heinz
    Mittendorf, Joachim
    Paulsen, Holger
    Platzek, Johannes
    Kolkhof, Peter
    CHEMMEDCHEM, 2012, 7 (08) : 1385 - 1403
  • [4] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist KBP-5074 in Individuals With Moderate Hepatic Impairment
    McCabe, James C.
    Benn, Vincent
    Zhang, Jay
    Yang, Y. Fred
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 392 - 392
  • [5] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
    McCabe, James
    Zhang, Jay
    Yang, Fred
    Benn, Vincent
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2024, 49 (02) : 229 - 237
  • [6] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
    James McCabe
    Jay Zhang
    Fred Yang
    Vincent Benn
    European Journal of Drug Metabolism and Pharmacokinetics, 2024, 49 : 229 - 237
  • [7] The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
    Roland Heinig
    Thomas Eissing
    Clinical Pharmacokinetics, 2023, 62 : 1673 - 1693
  • [8] The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
    Heinig, Roland
    Eissing, Thomas
    CLINICAL PHARMACOKINETICS, 2023, 62 (12) : 1673 - 1693
  • [9] Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist
    Kolkhof, P.
    Kretschmer, A.
    Baerfacker, L.
    Hartmann, E.
    Schaefer, S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 978 - 979
  • [10] Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure
    Delbeck, M.
    Kretschmer, A.
    Kast, R.
    Baerfacker, L.
    Hartmann, E.
    Schaefer, S.
    Kolkhof, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 772 - 773
1234